Researchers found that the medication that treat angina as well as the high pressure (HBP) protected against permanent damage in the cardiovascular system and kidneys triggered through acute kidney injuries (AKI) as per the findings of a study of mice that was that was published in Science Translational Medicine.
The researchers hope that their findings can to improve the treatment of people suffering from AKI that is typically caused by other diseases which can cause a decrease in the flow of blood to kidneys or due to toxicity from medication.
“AKI is a dangerous disease, especially for elderly people, and even after healing, it can cause lasting impact on one’s health. Our study has shown how blocking the endothelin pathway can prevent the long-term effects from AKI in mice.” Neeraj Dhaun, senior clinical lecturer and an honorary consultant nephrologist from the Edinburgh University’s Centre for Cardiovascular Science, stated in an announcement.
“As these medicines are already available for use in humans, I hope that we can move quickly to seeing if the same beneficial effects are seen in our patients,” He stated.
Researchers of University of Edinburgh. University of Edinburgh discovered that patients suffering from AKI had higher levels of endothelin. It is a protein that triggers swelling and makes blood vessels narrow. In addition, the levels of endothelin continued to be high even after kidney function was restored.
Following the discovery of the same amount of endothelin among mice suffering from AKI researchers administered a medication which blocked the endothelin-mediated system. The medicine, which is usually utilized to treat angina as well as HBP and HBP, functioned by blocking the endothelin receptors on cells, or preventing creation of the endothelin . The mice were observed for 4 weeks after AKI.
The researchers found that mice treated with the drug had less inflammation, less blood pressure and less kidney scarring. Additionally the blood vessels in their bodies were less tense and their kidney function improved when compared to mice that were not treated.
“Impaired kidney function that results from [AKI] can also increase a [individual’s] chance of developing and dying from heart and circulatory diseases, so it’s vital we find ways to reduce this risk,” James Leiper, medical director associate at the British Heart Foundation, said in an announcement.
“This positive research suggests that readily available medications could aid in tackling the effects of AKI before it causes injury and other complications. Although further research is required to prove that this treatment is suitable and safe to patients initial research is a positive initial step.” Leiper said.
The study was supported through the medical Research Council and the British Heart Foundation.
AKI is a decrease in kidney function, which can cause permanent kidney damage and even death, but it’s usually easily reversible or preventable as per the CDC.
A chronic kidney condition is usually an indicator of AKI as well as the reverse is also true.